Gothenburg, January 17, 2024 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, today announced that the company's Chief Scientific Officer and co-founder, Professor Magnus Essand, has received a prestigious speaking invitation from the Eighth International Cancer Immunotherapy Conference (CICON).
CICON is the world's largest recurring conference in the field of cancer immunotherapy and is being held this year in Washington, DC, between September 8 and 11.
"The fact that our co-founder and Chief Scientific Officer Magnus Essand has been invited as a speaker at the world's largest cancer immunotherapy conference, CICON, underlines the quality and level of innovation in Elicera Therapeutics' research platform. We are already looking forward to the opportunity to present our unique CAR T-cell therapies to a broad and initiated international audience in the US later this year,” said Jamal El-Mosleh, CEO of Elicera Therapeutics.
In his presentation, Magnus Essand will focus on the company's CAR T-cell programs ELC-301 and ELC-401, which are being developed for the treatment of diffuse large B-cell lymphoma and glioblastoma, respectively. Both programs use Elicera's unique iTANK technology platform to strengthen and broaden the effect of the treatments and reduce the risk of disease recurrence.
For further information please contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB
Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com
About the iTANK platform
The iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: tumor antigen heterogeneity and a hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating protein (NAP) from the bacterium Helicobacter pylori. NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company’s own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. The publication, titled “CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers” (DOI number: 10.1038/s41551-022-00875-5) can be found here: https://www.nature.com/articles/s41551-022-00875-5. More information about iTANK platform is available here: https://www.elicera.com/technology
About Elicera Therapeutics AB
Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company’s CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK-platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company’s share is traded on Nasdaq First North Growth Market. The company’s certified advisor is Carnegie Investment Bank AB (publ), www.carnegie.se. For additional information, visit www.elicera.com.